OpenAI purchases biotech software developer Orchestra Bio to strengthen drug discovery tools

OpenAI has acquired four-year-old software startup Orchestra Bio to accelerate its efforts in pharmaceutical research and drug development. While the financial terms of the deal were not disclosed, Orchestra had previously raised approximately $20 million as of 2025 from investors including Andreessen Horowitz, 8VC, and Atria. [1][2][3]

Orchestra builds specialized artificial intelligence agents designed to handle operational tasks for biotechnology teams, such as managing clinical trial schedules, tracking budgets, and keeping research programs on course. Under the agreement, Orchestra's staff and underlying technology will integrate directly into OpenAI's Rosalind life sciences division. [1][2]

OpenAI plans to incorporate Orchestra's tools into both its Rosalind life sciences AI model and the Rosalind Workbench, an interface intended to help scientists design experiments and interpret findings. The acquisition bolsters OpenAI's growing commercial footprint in healthcare, where prominent pharmaceutical clients such as Moderna and Novo Nordisk already deploy its technology. [2]